About John Worthington, MD
I am a psychiatrist seeing adult outpatients. I spend half of my time seeing patients in clinical research trials and half of my time seeing patients in our clinic.
Clinical Interests:
- Anxiety disorders
- Depressive disorders
- Grief and bereavement
- Psychopharmacology
- Trauma and critical care
- Treatment of alcohol, illicit drug use / abuse / dependence
Treats:
- Adult
Locations
Mass General Psychiatry: Center for Anxiety and Traumatic Stress Disorders
One Bowdoin Square
6th Floor
Boston, MA 02114
Phone: 866-449-6779
Medical Education
- MD, Georgetown University School of Medicine
- Residency, University of North Carolina
- Residency, University of North Carolina School of Medicine
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Psychiatry, American Board of Psychiatry and Neurology
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Commonwealth Care Alliance
- Coventry
- Evernorth Behavioral Health
- Humana
- MassHealth
- Medicaid NH
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Behavioral Health
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Dr. Worthington's areas of clinical research interests include the effects of alcohol and substance use on mood and anxiety disorders, acute and long-term treatment of patients with panic disorder and depression, development of novel pharmacologic agents for mood and anxiety disorders, and uses of combined cognitive-behavioral and pharmacologic therapies for treatment-refractory patients. Currently, Dr. Worthington is an investigator on several National Institutes of Mental Health studies. Amongst them is one involving the course of treatment-refractory social phobia and another one involves treatment strategies for posttraumatic stress disorder. He is also an investigator in numerous phase II and phase III clinical trials sponsored by several pharmaceutical companies. He has published over 140 articles, reviews and posters and he lectures in national and international forums.